Stock Traders Purchase High Volume of Ironwood Pharmaceuticals Call Options (IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was the target of some unusual options trading on Tuesday. Stock investors acquired 1,612 call options on the company. This is an increase of 1,496% compared to the typical volume of 101 call options.

In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 113,405 shares of Ironwood Pharmaceuticals stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the completion of the sale, the chief executive officer now directly owns 4,696,917 shares of the company’s stock, valued at approximately $71,017,385.04. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 115,769 shares of company stock valued at $1,752,491. 7.63% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. bought a new position in shares of Ironwood Pharmaceuticals in the 2nd quarter worth $1,472,000. Oppenheimer Asset Management Inc. raised its position in shares of Ironwood Pharmaceuticals by 592.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 17,878 shares of the biotechnology company’s stock worth $338,000 after acquiring an additional 15,295 shares in the last quarter. Granahan Investment Management Inc. MA raised its position in shares of Ironwood Pharmaceuticals by 24.5% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 436,000 shares of the biotechnology company’s stock worth $6,876,000 after acquiring an additional 85,904 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Ironwood Pharmaceuticals by 3.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 104,571 shares of the biotechnology company’s stock worth $1,974,000 after acquiring an additional 3,681 shares in the last quarter. Finally, First Trust Advisors LP raised its position in shares of Ironwood Pharmaceuticals by 20.3% in the 2nd quarter. First Trust Advisors LP now owns 94,732 shares of the biotechnology company’s stock worth $1,789,000 after acquiring an additional 16,018 shares in the last quarter.

Ironwood Pharmaceuticals (IRWD) opened at $15.12 on Friday. The company has a market capitalization of $2,260.00, a price-to-earnings ratio of -15.75 and a beta of 1.45. The company has a debt-to-equity ratio of -22.31, a current ratio of 4.87 and a quick ratio of 4.86. Ironwood Pharmaceuticals has a 1 year low of $13.43 and a 1 year high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. The firm had revenue of $86.80 million during the quarter, compared to analyst estimates of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The business’s revenue for the quarter was up 31.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.18) EPS. research analysts anticipate that Ironwood Pharmaceuticals will post -1.12 earnings per share for the current year.

A number of equities research analysts have weighed in on IRWD shares. Credit Suisse Group started coverage on Ironwood Pharmaceuticals in a research report on Monday, November 27th. They set a “buy” rating and a $19.00 target price for the company. ValuEngine lowered Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Mizuho lowered Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $20.00 to $16.00 in a research report on Wednesday, December 6th. Morgan Stanley reaffirmed a “hold” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 4th. Finally, BidaskClub lowered Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 30th. Four analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. Ironwood Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $17.56.

COPYRIGHT VIOLATION WARNING: This story was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.themarketsdaily.com/2018/01/14/stock-traders-purchase-high-volume-of-ironwood-pharmaceuticals-call-options-irwd.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply